A study may contain one encouraging result without its main comparison being decisive. That does not make the finding worthless, but it does change how it should be described. Supplement marketing often loses this distinction when a subgroup becomes the entire headline.

The evidence in context

A twelve-week trial in young men compared pea protein, whey and placebo during upper-body resistance training. Overall differences in muscle thickness between groups were not clearly significant; a subgroup with lower starting strength showed an advantage for pea protein over placebo. Strength gains did not differ clearly between groups. [1]

A favourable subgroup cannot establish that pea protein is superior for everyone. The participants, training programme and measured muscles also limit how widely the findings apply.

Follow the comparison back to its source

Ask whether the advertised benefit appeared in the whole study or only in selected participants. Also check whether it concerned muscle size, strength or both. In this protein trial, a specific muscle-size subgroup result should not become a general promise of greater strength.

Putting it into perspective

A subgroup may be defined by starting strength, age or another characteristic. It can generate an interesting lead for future work, but it should remain visible as a subgroup. If the headline drops that detail, a result applying to selected participants can look like the main finding for everyone.